Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO Subscriptions PDA Services My JCO Customer Service

Journal of Clinical Oncology, Vol 24, No 8 (March 10), 2006: pp. 1281-1288
© 2006 American Society of Clinical Oncology.
DOI: 10.1200/JCO.2005.04.8819

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Batchelor, T.
Right arrow Articles by Loeffler, J. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Batchelor, T.
Right arrow Articles by Loeffler, J. S.

REVIEW ARTICLE

Primary CNS Lymphoma

Tracy Batchelor, Jay S. Loeffler

From the Stephen E. and Catherine Pappas Center for Neuro-Oncology, Massachusetts General Hospital; Division of Neuro-Oncology, Department of Neurology, and Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA

Address reprint requests to Tracy Batchelor, MD, MPH, Yawkey 9E, Massachusetts General Hospital, 55 Fruit St, Boston, MA 02114; e-mail: tbatchelor{at}partners.org

Primary CNS lymphoma (PCNSL), an uncommon form of extranodal non-Hodgkin's lymphoma (NHL), has increased in incidence during the last three decades and occurs in both immunocompromised and immunocompetent hosts. PCNSL in immunocompetent patients is associated with unique diagnostic, prognostic, and therapeutic issues, and the management of this malignancy is different from that of other forms of extranodal NHL. Characteristic imaging features should be suggestive of the diagnosis, avoidance of corticosteroids, if possible, and early neurosurgical consultation for stereotactic biopsy. Because PCNSL may involve the brain, CSF, and eyes, diagnostic evaluation should include assessment of all of these regions as well as screening for possible occult systemic disease. Resection provides no therapeutic benefit and should be reserved for the rare patient with neurologic deterioration due to brain herniation. Whole-brain radiation therapy (WBRT) alone is insufficient for durable tumor control and is associated with a high risk of neurotoxicity in patients older than age 60. Neurotoxicity typically is associated with significant cognitive, motor, and autonomic dysfunction, and has a negative impact on quality of life. Chemotherapy and WBRT together improve tumor response rates and survival compared with WBRT alone. Methotrexate-based multiagent chemotherapy without WBRT is associated with similar tumor response rates and survival compared with regimens that include WBRT, although controlled trials have not been performed. The risk of neurotoxicity is lower in patients treated with chemotherapy alone.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.




This article has been cited by other articles:


Home page
JCOHome page
W. Huh, J. Ho Han, C.-K. Park, and S.-H. Park
Primary CNS Lymphoma Presenting With Acute Blindness and Encephalocele
J. Clin. Oncol., February 1, 2008; 26(4): 678 - 679.
[Full Text] [PDF]


Home page
Br. J. Ophthalmol.Home page
J Vicuna-Kojchen, S Frenkel, T Siegal, E Shalom, I Chowers, and J Pe'er
Maculopathy in patients with primary CNS lymphoma treated with chemotherapy in conjunction with blood-brain barrier disruption
Br. J. Ophthalmol., February 1, 2008; 92(2): 231 - 235.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
N. D. Doolittle, L. E. Abrey, T. N. Shenkier, S. Tali, J. E.C. Bromberg, E. A. Neuwelt, C. Soussain, K. Jahnke, P. Johnston, G. Illerhaus, et al.
Brain parenchyma involvement as isolated central nervous system relapse of systemic non-Hodgkin lymphoma: an International Primary CNS Lymphoma Collaborative Group report
Blood, February 1, 2008; 111(3): 1085 - 1093.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
J. O. Armitage
How I treat patients with diffuse large B-cell lymphoma
Blood, July 1, 2007; 110(1): 29 - 36.
[Full Text] [PDF]


Home page
haematolHome page
M. Booman, J. Douwes, M.-C. Legdeur, J. van Baarlen, E. Schuuring, and P. Kluin
From brain to testis: immune escape and clonal selection in a B cell lymphoma with selective out-growth in two immune sanctuariesy
Haematologica, June 1, 2007; 92(6): e69 - e71.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
C. Soussain, L. L. Muldoon, C. Varallyay, K. Jahnke, L. DePaula, and E. A. Neuwelt
Characterization and Magnetic Resonance Imaging of a Rat Model of Human B-Cell Central Nervous System Lymphoma
Clin. Cancer Res., April 15, 2007; 13(8): 2504 - 2511.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
T. S. Lawrence, J. C. Buckner, and F. F. Lang
CNS Malignancies: At Last, Real Progress
J. Clin. Oncol., March 10, 2006; 24(8): 1225 - 1227.
[Full Text] [PDF]



About
JCO
 Editorial
Roster
 Advertising
Information
 Librarians &
Institutions
 Rights &
Permissions
 Site Map

Copyright © 2006 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online